LKT Laboratories, Inc.

Tandutinib

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID T0152
CAS No. 387867-13-2
Chemical Name

Synonym CT53518; MLN518

Formula $C_{31}H_{42}N_6O_4$
Formula Wt. 562.7
Melting Point 177-178°C
Purity ≥98%
Solubility



Pricing and Availability

Bulk quanitites available upon request

Product ID	Size	List Price
T0152	1 mg	$88.60
T0152	5 mg	$420.90
T0152	25 mg	$1018.80

Store Temp Ambient
Ship Temp Ambient

Description Tandutinib is an inhibitor of several kinases, including FMS-like tyrosine kinase 3 (FLT3), PDGFR, and Kit. Tandutinib exhibits anticancer chemotherapeutic and anti-angiogenic activities and currently shows mixed results in clinical trials as a potential treatment for several cancers. In vivo, tandutinib inhibits phosphorylation of c-Kit, Akt, mTOR, and p70S6 kinase; it also increases activation of caspase 3 and the ratio of Bax/Bcl-2 and decreases expression of cyclin D1, resulting in apoptosis. In animal models, tandutinib decreases expression of COX-2 and VEGF, decreasing vessel formation and inhibiting growth of colon cancer xenografts. In an in vivo model of medulloblastoma, this compound decreases tumor volume.

References

Ponnurangam S, Standing D, Rangarajan P, et al. Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth. Mol Cancer Ther. 2013 May;12(5):598-609. PMID: 23427297.

Ohshima-Hosoyama S, Davare MA, Prajapati SI, et al. Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model. J Pediatr Hematol Oncol. 2012 Mar;34(2):116-21. PMID: 22146535.

Griswold IJ, Shen LJ, La Rosée P, et al. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood. 2004 Nov 1;104(9):2912-8. PMID: 15242881.